Chronic myelomonocytic leukemia (CMML) can be a difficult disease to treat. Unfortunately, lasting remissions aren't common. You should discuss survival information with your doctor.
The reported median survival of people diagnosed with CMML is from 12 to 24 months after the start of treatment. Keep in mind that outcome data can show how other people with CMML responded to treatment but can't predict how any one person will respond. Also, statistics may underestimate survival to a small degree since they may not reflect the most recent advances in treatment.
Many factors influence patient survival. Factors that may indicate a less favorable outcome include:
- severe anemia
- a high percentage of blast cells in the blood
- a high number of white cells called leukocytes in the blood
- a high level of the protein lactate dehydrogenase (LDH) in the blood
- an enlarged spleen
The disease progresses to acute myeloid leukemia in about 20 percent of CMML patients.
The reclassification of CMML by the World Health Organization in 2001 is expected to lead to a greater understanding of the disease and to the development of more effective treatments.